This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page
About Zinforo

About Zinforo

OverviewExtended spectrum coverageDosing

Dosing

Adult & adolescent dosingNeonatal & paediatric dosingEfficacy & Safety

Efficacy & Safety

EfficacyFOCUS Phase III Trial (CAP)CANVAS Phase III Trial (cSSTI)ASIA CAP Phase III TrialPaediatric EfficacyAdult safetyPaediatric SafetyClinical & Scientific Data

Clinical & Scientific Data

Patient Risk FactorsCAP patient profilescSSTI patient profilesCAPTURE studySupport & Resources

Support & Resources

Videos & case studiesVideos
Materials

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Identifying a cSSTI patient who may benefit from Zinforo®​​​​​​​In cSSTI patients, initial antimicrobial therapy failure is associated with 4-11 days longer in hospital and 4-12x higher mortality2-4Laura, 71-year-old diabetic with cellulitis, presented with tender erythematous, non-raised lesions*

Severity:​​​​​​​

  • Deep and extensive cellulitis on the right leg that extends mid-calf to the ankle (~275 cm2)
  • Signs of systemic inflammatory response (Temp >38°C)
  • Rapid spread of erythema over past 24 hours

History/comorbidities:​​​​​​​

  • History of smoking
  • Type 2 insulin-dependent diabetes HbA1c= 7.4%

Risk factors for difficult-to-treat infection:​​​​​​​

  • ​​​​​​​Nursing home resident
  • Poorly managed diabetes
Martin, 44-year-old readmitted to hospital following inguinal hernia repair with purulent drainage from incision and localised pain*

Severity:

  • ​​​​​​​Signs of systemic inflammatory response (temp >38°C and heart rate >90 bpm)

History/comorbidities:​​​​​​

  • ​​​​​​​History of depression (currently controlled by medication)
  • Obese (weight = 132 kg; BMI = 37)​​​​​​​

Risk factors for difficult-to-treat infection

  • ​​​​​​​MRSA colonisation identified during admission screening for surgery
Mark, 67-year-old admitted to Accident and Emergency with a painful and fluctuant gluteal abscess*

Severity:

Mark, 67-year-old admitted to Accident and Emergency with a painful and fluctuant gluteal abscess*
  • Abscess area 12 cm2 with 95 cm2 surrounding cellulitis
  • Rapidly spreading infection
  • Signs of systemic inflammatory response (temp >38°C, heart rate >90 bpm, RR >20/min)

History/comorbidities:

  • ​​​​​​​Chronic renal impairment- CrCL at hospital admission = 17 mL/min

Risk factors for difficult-to-treat infection:​

  • Chronic renal disease
  • Treatment with fluoroquinolone within 6 months for UTI

When there's no time to wait, Zinforo provides swift, decisive action against cSSTIs†1,5,6

Learn about proven efficacy in cSSTI patients​​​​​​​

Explore More Read several CAP patient profiles describing potential scenarios where Zinforo could be a treatment of choice. Access CAP patient profiles Loading To learn more about the efficacy of Zinforo in a real-world setting, explore the CAPTURE study.  View CAPTURE study data Loading

*The examples described here are not actual patients, but fictitious representations of scenarios for which Zinforo could be considered.
†Refer to SmPC for further information on Zinforo.1​​​​

Abbreviations

​​​​​​​CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CE, clinically evaluable; CANVAS, Ceftaroline fosamil vs Vancomycin in Skin and skin structure infection; CI, confidence interval; MITT, modified intent-to-treat; PORT, Pneumonia Patient Outcomes Research Team; MRSA, Methicillin-resistant Staphylococcus aureus. 

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)

Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion

Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 

References

ZINFORO. Summary of Product CharacteristicsBerger A, et al. Surg Infect 2013;14;304-12Edelsberg J, et al. Infect Control Hosp Epidemiol 2008;29:160-9Ostermann H, et al. J Med Econ 2013;17:719-29Corey G, et al. Clin Infect Dis 2010;51:641-50Friedland D, et al. Antimicrob Agents Chemother 2012;56:2231-6Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103Drusano, GL. J Antimicrob Chemother 2011;66(Suppl3):iii61–7
PP-ZFO-GBR-0232. September 2021
Tolerability profile of Zinforo

Access data on the tolerability profile of Zinforo as established in key Phase III clinical trials

 view safety profile Loading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284 November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​